Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment techniques of gastrointestinal small lesions. Postoperative rebleeding is one of the common complication following EMR. Several endoscopic hemostasis methods are currently in use. EndoClot® absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic application remains unknown. This study has been designed to observe the effect of rebleeding prevention after EMR.
Study Type
OBSERVATIONAL
Enrollment
164
EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Xijing Hospital of Digestive Diseases
Xi’an, Shanxi, China
Rebleeding rate after EMR procedure
Rebleeding rate up to 1 week was obtained by clinical manifestations such as melana; decreased hemoglobin \> 20g/L; hemodynamic instability or active bleeding from mucosal defect under endoscope.
Time frame: up to 1 week
Mucosal healing after EMR
Colonoscopy will be repeated 1 month after EMR procedure to observe if application of Endoclot will delay the musosal healing.
Time frame: up to 1 month
gastrointestinal tract obstruction
Gastrointestinal tract obstruction has been previously reported as a possible adverse effect of hemostats, therefore it was observed in the current study.
Time frame: up to 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.